BR112018010639A2 - método de transfecção transitória para produção retroviral. - Google Patents
método de transfecção transitória para produção retroviral.Info
- Publication number
- BR112018010639A2 BR112018010639A2 BR112018010639A BR112018010639A BR112018010639A2 BR 112018010639 A2 BR112018010639 A2 BR 112018010639A2 BR 112018010639 A BR112018010639 A BR 112018010639A BR 112018010639 A BR112018010639 A BR 112018010639A BR 112018010639 A2 BR112018010639 A2 BR 112018010639A2
- Authority
- BR
- Brazil
- Prior art keywords
- nucleic acid
- transient transfection
- transfection method
- retroviral
- retroviral production
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 230000001177 retroviral effect Effects 0.000 title abstract 3
- 238000003146 transient transfection Methods 0.000 title abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 239000013598 vector Substances 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004414 DNA Proteins 0.000 abstract 1
- 101710177291 Gag polyprotein Proteins 0.000 abstract 1
- 102100034353 Integrase Human genes 0.000 abstract 1
- 101710125418 Major capsid protein Proteins 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 108010078428 env Gene Products Proteins 0.000 abstract 1
- 108010089520 pol Gene Products Proteins 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
- C12N15/895—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection using biolistic methods
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
- C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/50—Vectors for producing vectors
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1520764.0A GB201520764D0 (en) | 2015-11-24 | 2015-11-24 | Transient transfection method for retroviral production |
| GBGB1609354.4A GB201609354D0 (en) | 2016-05-26 | 2016-05-26 | Transient transfection method for retroviral production |
| PCT/EP2016/078334 WO2017089307A1 (en) | 2015-11-24 | 2016-11-21 | Transient transfection method for retroviral production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018010639A2 true BR112018010639A2 (pt) | 2019-01-22 |
Family
ID=57348703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018010639A BR112018010639A2 (pt) | 2015-11-24 | 2016-11-21 | método de transfecção transitória para produção retroviral. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10450574B2 (enExample) |
| EP (1) | EP3380605A1 (enExample) |
| JP (1) | JP7110096B2 (enExample) |
| KR (1) | KR102067352B1 (enExample) |
| CN (1) | CN108291211A (enExample) |
| AU (1) | AU2016359838B2 (enExample) |
| BR (1) | BR112018010639A2 (enExample) |
| CA (1) | CA3006285A1 (enExample) |
| DE (1) | DE102016122317A1 (enExample) |
| FR (1) | FR3044017B1 (enExample) |
| IL (1) | IL259223B (enExample) |
| IT (1) | IT201600117287A1 (enExample) |
| RU (1) | RU2749717C2 (enExample) |
| SA (1) | SA518391585B1 (enExample) |
| WO (1) | WO2017089307A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3294756B1 (fr) * | 2015-05-15 | 2020-12-02 | Flash Therapeutics | Particule rétrovirale comportant au moins deux arn non viraux encapsidés différents |
| RU2752498C2 (ru) * | 2015-11-24 | 2021-07-28 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Стабильные клеточные линии для продуцирования ретровирусов |
| GB201706121D0 (en) | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Stable cell lines for retroviral production |
| GB201715052D0 (en) | 2017-09-19 | 2017-11-01 | Oxford Genetics Ltd | Vectors |
| EP3633040B1 (en) * | 2017-12-22 | 2023-06-07 | Oxford BioMedica (UK) Limited | Retroviral vector |
| GB201816919D0 (en) * | 2018-10-17 | 2018-11-28 | Glaxosmithkline Ip Dev Ltd | Adeno-associated viral vector producer cell lines |
| CN110684804B (zh) * | 2019-10-15 | 2023-04-18 | 上海本导基因技术有限公司 | 递送外源rnp的慢病毒载体及其制备方法 |
| GB202004371D0 (en) | 2020-03-26 | 2020-05-13 | Glaxosmithkline Ip Dev Ltd | CAR constructs |
| GB202005096D0 (en) | 2020-04-07 | 2020-05-20 | Glaxosmithkline | Modified vectors for production of retrovirus |
| AU2021253701B2 (en) * | 2020-04-10 | 2024-05-02 | Southwest Research Institute | Three-dimensional bioreactor for viral vector production |
| CA3212615A1 (en) | 2021-03-19 | 2022-09-22 | Glaxosmithkline Intellectual Property Development Limited | Chimeric antigen receptors targeting claudin-3 and methods for treating cancer |
| CN113373266B (zh) * | 2021-06-22 | 2022-07-01 | 内蒙古农业大学 | 一种用于检测绵羊肺腺瘤病毒的荧光rpa引物、试剂盒和检测方法 |
| WO2024218341A1 (en) | 2023-04-19 | 2024-10-24 | Glaxosmithkline Intellectual Property Development Limited | Cytotoxicity targeting chimeras for car-t and car-nk cells |
| WO2024218345A1 (en) | 2023-04-21 | 2024-10-24 | Glaxosmithkline Intellectual Property Development Limited | Cytotoxicity targeting chimeras for antibody-drug conjugates and bispecific antibodies |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5593972A (en) * | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| WO1995003400A1 (en) * | 1993-07-23 | 1995-02-02 | Johns Hopkins University School Of Medicine | Recombinationally targeted cloning in yeast artificial chromosomes |
| NZ312671A (en) * | 1995-06-27 | 1999-10-28 | Bavarian Nordic Res Inst As | Capsules of encapsulating cells producing viral particles |
| JP2000504585A (ja) | 1996-02-13 | 2000-04-18 | フレッド ハッチンソン カンサー リサーチ センター | １０ａ１レトロウィルスパッケージング細胞及びその使用 |
| FR2751223B1 (fr) * | 1996-07-19 | 1998-12-04 | Rhone Merieux | Formule de vaccin polynucleotidique felin |
| US6277621B1 (en) * | 1998-02-26 | 2001-08-21 | Medigene, Inc. | Artificial chromosome constructs containing foreign nucleic acid sequences |
| CA2358915C (en) | 1998-12-31 | 2010-06-01 | Chiron Corporation | Modified hiv env polypeptides |
| US6677155B1 (en) | 1999-04-22 | 2004-01-13 | The General Hospital Corporation | Triple hybrid amplicon vector systems to generate retroviral packaging lines |
| EP1179083A4 (en) | 1999-04-22 | 2003-04-23 | Gen Hospital Corp | TRIPLE HYBRID AMPLICON VECTOR SYSTEMS FOR THE PRODUCTION OF RETROVIRUS PACKING CELL LINES |
| EP1173597A1 (en) | 1999-04-29 | 2002-01-23 | Aarhus University | Expression of heterologous genes from an ires translational cassette in retroviral vectors |
| US7083971B1 (en) | 1999-06-07 | 2006-08-01 | Cell Genesys, Inc. | Hybrid yeast-bacteria cloning system and uses thereof |
| PT1792997E (pt) | 1999-10-12 | 2012-02-02 | Pasteur Institut | Adn triplex lentiviral, vetores e células recombiantes contendo adn triplex lentiviral |
| AU2001265187A1 (en) * | 2000-05-30 | 2001-12-11 | Baylor College Of Medicine | Chimeric viral vectors for gene therapy |
| WO2002022663A2 (en) | 2000-09-18 | 2002-03-21 | Maxygen, Inc. | Stress resistant retroviruses |
| US6586251B2 (en) * | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7214515B2 (en) | 2001-01-05 | 2007-05-08 | The General Hospital Corporation | Viral delivery system for infectious transfer of large genomic DNA inserts |
| DE10111433A1 (de) | 2001-03-09 | 2002-09-19 | Bundesrepublik Deutschland Let | Replikationskompetente molekulare Klone von porcinem endogenem Retrovirus der Klasse A und Klasse B,abgeleitet von Schweine- und humanen Zellen |
| US20030119104A1 (en) | 2001-05-30 | 2003-06-26 | Edward Perkins | Chromosome-based platforms |
| US6835568B2 (en) * | 2001-10-30 | 2004-12-28 | Virxsys Corporation | Regulated nucleic acid expression system |
| JP4598398B2 (ja) | 2002-02-01 | 2010-12-15 | オックスフォード バイオメディカ （ユーケー） リミテッド | ウイルスベクター |
| EP1495125B1 (en) | 2002-04-10 | 2010-06-16 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Vac-bac shuttle vector system |
| EA012723B1 (ru) * | 2002-11-25 | 2009-12-30 | Бавариан Нордик А/С | Рекомбинантный поксвирус, содержащий по меньшей мере два промотора ati вируса коровьей оспы, и его применение |
| WO2005106002A2 (en) * | 2004-04-28 | 2005-11-10 | The Trustees Of The University Of Pennsylvania | Polyvalent viral vectors and a system for production thereof |
| US20080226677A1 (en) | 2004-05-06 | 2008-09-18 | Yasuko Mori | Recombinant virus vector for gene transfer into lymphoid cells |
| EP1652932A1 (en) | 2004-11-02 | 2006-05-03 | GBF Gesellschaft für Biotechnologische Forschung mbH | Method for the generation of virus producing cell lines and cell lines |
| ATE495246T1 (de) * | 2004-11-24 | 2011-01-15 | Anaeropharma Science Inc | Neuartiger shuttle-vektor |
| CN101065492A (zh) | 2004-11-24 | 2007-10-31 | 纳诺非科特有限公司 | 病毒载体 |
| US20120121650A1 (en) | 2006-08-18 | 2012-05-17 | Johnston Robert E | Chimeric Virus Vaccines |
| GB0702695D0 (en) * | 2007-02-12 | 2007-03-21 | Ark Therapeutics Ltd | Production of vectors |
| EP2137296A2 (en) * | 2007-03-23 | 2009-12-30 | Wisconsin Alumni Research Foundation | Somatic cell reprogramming |
| US20110027313A1 (en) | 2008-04-04 | 2011-02-03 | University Of Miami | Viral recombineering and uses thereof |
| EP2480678B1 (en) | 2010-09-02 | 2014-02-12 | Molmed SpA | Stable production of lentiviral vectors |
| US9273324B2 (en) | 2010-12-05 | 2016-03-01 | Andrew S. Belmont | Recombinant gene expression |
| WO2012170431A2 (en) | 2011-06-06 | 2012-12-13 | Bluebird Bio, Inc. | Improved geneswitch systems |
| GB201202516D0 (en) | 2012-02-13 | 2012-03-28 | Ucl Business Plc | Materials and methods relating to packaging cell lines |
| JP2015529466A (ja) * | 2012-09-14 | 2015-10-08 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 鎌状赤血球症の幹細胞遺伝子治療のためのレンチウイルスベクター |
| EP3117004A4 (en) * | 2014-03-14 | 2017-12-06 | University of Washington | Genomic insulator elements and uses thereof |
| GB2538321A (en) | 2015-05-15 | 2016-11-16 | Glaxosmithkline Ip Dev Ltd | Artificial chromosome for retroviral production |
| GB2538324A (en) | 2015-05-15 | 2016-11-16 | Glaxosmithkline Ip Dev Ltd | Packaging cell line for retroviral production |
| KR102058113B1 (ko) * | 2015-11-23 | 2019-12-23 | 주식회사 엘지화학 | 접착력이 개선된 리튬 이차전지용 전극 및 이의 제조방법 |
| RU2752498C2 (ru) | 2015-11-24 | 2021-07-28 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Стабильные клеточные линии для продуцирования ретровирусов |
-
2016
- 2016-11-21 US US15/356,813 patent/US10450574B2/en active Active
- 2016-11-21 BR BR112018010639A patent/BR112018010639A2/pt not_active Application Discontinuation
- 2016-11-21 CN CN201680068697.3A patent/CN108291211A/zh active Pending
- 2016-11-21 CA CA3006285A patent/CA3006285A1/en active Pending
- 2016-11-21 FR FR1661254A patent/FR3044017B1/fr not_active Expired - Fee Related
- 2016-11-21 EP EP16798223.0A patent/EP3380605A1/en not_active Withdrawn
- 2016-11-21 JP JP2018526787A patent/JP7110096B2/ja active Active
- 2016-11-21 RU RU2018118964A patent/RU2749717C2/ru active
- 2016-11-21 IT IT102016000117287A patent/IT201600117287A1/it unknown
- 2016-11-21 AU AU2016359838A patent/AU2016359838B2/en not_active Ceased
- 2016-11-21 KR KR1020187014239A patent/KR102067352B1/ko not_active Expired - Fee Related
- 2016-11-21 WO PCT/EP2016/078334 patent/WO2017089307A1/en not_active Ceased
- 2016-11-21 DE DE102016122317.4A patent/DE102016122317A1/de not_active Withdrawn
-
2018
- 2018-05-08 IL IL259223A patent/IL259223B/en unknown
- 2018-05-15 SA SA518391585A patent/SA518391585B1/ar unknown
-
2019
- 2019-10-21 US US16/658,293 patent/US20200063144A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20200063144A1 (en) | 2020-02-27 |
| RU2749717C2 (ru) | 2021-06-16 |
| US10450574B2 (en) | 2019-10-22 |
| JP2019500030A (ja) | 2019-01-10 |
| WO2017089307A1 (en) | 2017-06-01 |
| IL259223A (en) | 2018-07-31 |
| AU2016359838A1 (en) | 2018-05-24 |
| DE102016122317A1 (de) | 2017-05-24 |
| KR102067352B1 (ko) | 2020-01-16 |
| FR3044017B1 (fr) | 2019-05-03 |
| EP3380605A1 (en) | 2018-10-03 |
| AU2016359838B2 (en) | 2020-08-06 |
| JP7110096B2 (ja) | 2022-08-01 |
| RU2018118964A (ru) | 2019-12-26 |
| US20170145427A1 (en) | 2017-05-25 |
| CA3006285A1 (en) | 2017-06-01 |
| FR3044017A1 (fr) | 2017-05-26 |
| SA518391585B1 (ar) | 2020-10-26 |
| IL259223B (en) | 2022-05-01 |
| KR20180073624A (ko) | 2018-07-02 |
| CN108291211A (zh) | 2018-07-17 |
| RU2018118964A3 (enExample) | 2020-04-02 |
| IT201600117287A1 (it) | 2018-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018010639A2 (pt) | método de transfecção transitória para produção retroviral. | |
| BR112018010635A2 (pt) | linhagens celulares estáveis para a produção retroviral | |
| CY1122175T1 (el) | Δομες πολυειδικου αντισωματος | |
| CL2021002739A1 (es) | Proteína crispr de prevotella y francisella 1 (cpf1) aislada de acidaminococcus sp. bv3l6; proteína de fusión que la comprende; ácido nucleico; vector; métodos para alterar el genoma de una célula o una molécula de adn bicatenario in vitro que utilizan dichas proteínas (divisional de sol. 201903004) | |
| BR112019006384A2 (pt) | enzimas modificadoras de ácido nucleico guiadas por rna e métodos de uso das mesmas | |
| BR112019006388A2 (pt) | enzimas modificadoras de ácido nucleico guiadas por rna e métodos de uso das mesmas | |
| CY1123697T1 (el) | Θεραπεια της amd με χρηση της παραλλαγης aav2 με αφλιβερσεπτη | |
| ZA202001294B (en) | Multispecific antibody | |
| CO2019006485A2 (es) | Anticuerpos y metodos de su utilizacion | |
| MX2017016688A (es) | Nuevas enzimas y sistemas crispr. | |
| MX2016012716A (es) | Compuestos y metodos para suministro trans-membrana de moleculas. | |
| BR112019007369A2 (pt) | anticorpos anti-lag-3 e métodos de uso dos mesmos | |
| CO2019002609A2 (es) | Proteínas de unión recombinantes y sus usos | |
| BR112018000477A2 (pt) | proteína de ligação de imunoglobulina não natural, composição, uso da proteína de ligação de ig não natural, método de purificação de afinidade de imunoglobulinas, método de geração de uma proteína de ligação de imunoglobulina não natural, molécula de ácido nucleico, vetor, célula hospedeira ou um hospedeiro não humano, e método para a produção de uma proteína de ligação de imunoglobulina não natural | |
| BR112018067536A2 (pt) | sistema de transpóson e métodos de uso | |
| BR112017020986A2 (pt) | proteínas de ligação recombinantes e seu uso | |
| BR112018074325A2 (pt) | anticorpo para ligação a receptor de interleucina 4 | |
| MX390848B (es) | Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos. | |
| MX391311B (es) | Acidos nucleicos modificados dirigidos a acidos nucleicos. | |
| MX2017014908A (es) | Proteinas de union triespecificas y metodos de uso. | |
| BR112017009728A2 (pt) | anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio | |
| MX2019007248A (es) | Enzimas de polimerizacion para reacciones de secuenciacion. | |
| CY1123403T1 (el) | Τροποποιημενα κυτταρα ξενιστες και χρησεις αυτων | |
| MX2021001578A (es) | Proteina asociada a crispr novedosa y uso de la misma. | |
| BR112016015936A2 (pt) | Combinação imunogênica, molécula de ácido nucleico, vetor, célula hospedeira, método de produção recombinante dos antígenos e composição |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |